Patents by Inventor Consuelo M. Blosch

Consuelo M. Blosch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020974
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020968
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020979
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020980
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020986
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020977
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020982
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020976
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020985
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020975
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020981
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020965
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020987
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020972
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020966
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020978
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9545434
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: January 17, 2017
    Assignee: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9545435
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: January 17, 2017
    Assignee: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9539310
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: January 10, 2017
    Assignee: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20150290296
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: June 19, 2015
    Publication date: October 15, 2015
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch